Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 41, Issue 4, 2014, Pages 375-387

  Cao, Yanguang ^a   Jusko, William J ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Minimal PBPK; Monoclonal antibody; PBPK; Target mediated drug disposition

Indexed keywords

MONOCLONAL ANTIBODY; DRUG RECEPTOR;

ARTICLE; COMPARTMENT MODEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG EXTRAVASATION; DRUG RECEPTOR BINDING; FEASIBILITY STUDY; INTERSTITIAL FLUID; MATHEMATICAL MODEL; NONLINEAR SYSTEM; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; RELIABILITY; ADULT; ALGORITHM; ANIMAL; BLOOD; COMPUTER SIMULATION; FEMALE; HAPLORHINI; HUMAN; MALE; MIDDLE AGED; STATISTICAL MODEL; TISSUE DISTRIBUTION;

ADULT; ALGORITHMS; ANIMALS; ANTIBODIES, MONOCLONAL; COMPUTER SIMULATION; FEMALE; HAPLORHINI; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; NONLINEAR DYNAMICS; RECEPTORS, DRUG; TISSUE DISTRIBUTION;

EID: 84906938717     PISSN: 1567567X     EISSN: 15738744     Source Type: Journal    
DOI: 10.1007/s10928-014-9372-2     Document Type: Article

References (39)

1. Buss NA, Henderson SJ, McFarlane M, Shenton JM, de Haan L (2012) Monoclonal antibody therapeutics: history and future. Curr Opin Pharmacol 12:615-622
2. Reichert JM (2012) Marketed therapeutic antibodies compendium. MAbs 4:413-415
3. Wang W, Wang EQ, Balthasar JP (2008) Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 84:548-558
4. Cao Y, Jusko WJ (2012) Applications of minimal physiologically-based pharmacokinetic models. J Pharmacokinet Pharmacodyn 39:711-723
5. Cao Y, Balthasar JP, Jusko WJ (2013) Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies. J Pharmacokinet Pharmacodyn 40:597-607
6. Cao Y, Jusko WJ (2014) Survey of monoclonal antibody disposition in man utilizing a minimal physiologically-based pharmacokinetic model. J Pharmacokinet Pharmacodyn (under review)
7. Levy G (1994) Pharmacologic target-mediated drug disposition. Clin Pharmacol Ther 56:248-252
8. Mager DE, Jusko WJ (2001) General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 28:507-532 (Pubitemid 34289541)
9. Luu KT, Bergqvist S, Chen E, Hu-Lowe D, Kraynov E (2012) A model-based approach to predicting the human pharmacokinetics of a monoclonal antibody exhibiting target-mediated drug disposition. J Pharmacol Exp Ther 341:702-708
10. Woo S, Krzyzanski W, Jusko WJ (2007) Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO). J Pharmacokinet Pharmacodyn 34:849-868 (Pubitemid 350165278)
11. Yamazaki S, Shen Z, Jiang Y, Smith BJ, Vicini P (2013) Application of target-mediated drug disposition model to small molecule heat shock protein 90 inhibitors. Drug Metab Dispos 41:1285-1294
12. Ng CM, Stefanich E, Anand BS, Fielder PJ, Vaickus L (2006) Pharmacokinetics/pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1) in healthy human volunteers. Pharm Res 23:95-103 (Pubitemid 43214665)
13. Gibiansky L, Gibiansky E, Kakkar T, Ma P (2008) Approximations of the target-mediated drug disposition model and identifiability of model parameters. J Pharmacokinet Pharmacodyn 35:573-591
14. Garg A, Balthasar JP (2007) Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J Pharmacokinet Pharmacodyn 34:687-709 (Pubitemid 47477039)
15. Shah DK, Betts AM (2012) Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J Pharmacokinet Pharmacodyn 39:67-86
16. Pang KS, Rowland M (1977) Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm 5:625-653 (Pubitemid 8253670)
17. Boswell CA, Tesar DB, Mukhyala K, Theil FP, Fielder PJ, Khawli LA (2010) Effects of charge on antibody tissue distribution and pharmacokinetics. Bioconjug Chem 21:2153-2163
18. Nugent LJ, Jain RK (1984) Extravascular diffusion in normal and neoplastic tissues. Cancer Res 44:238-244 (Pubitemid 14177745)
19. Gerlowski LE, Jain RK (1986) Microvascular permeability of normal and neoplastic tissues. Microvasc Res 31:288-305 (Pubitemid 16076428)
20. Lammerts van Bueren JJ, Bleeker WK, Bogh HO, Houtkamp M, Schuurman J, van de Winkel JG, Parren PW (2006) Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action. Cancer Res 66:7630-7638 (Pubitemid 44289220)
21. Tokuda Y, Watanabe T, Omuro Y, Ando M, Katsumata N, Okumura A, Ohta M, Fujii H, Sasaki Y, Niwa T et al (1999) Dose escalation and pharmacokinetic study of a humanized anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. Br J Cancer 81:1419-1425
22. Xiang H, Bender BC, Reyes AE 2nd, Merchant M, Jumbe NL, Romero M, Davancaze T, Nijem I, Mai E, Young J et al (2013) Onartuzumab (MetMAb): using nonclinical pharmacokinetic and concentration-effect data to support clinical development. Clin Cancer Res 19:5068-5078
23. Kamath AV, Lu D, Gupta P, Jin D, Xiang H, Wong A, Leddy C, Crocker L, Schaefer G, Sliwkowski MX et al (2012) Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose. Cancer Chemother Pharmacol 69:1063-1069
24. Padhi D, Jang G, Stouch B, Fang L, Posvar E (2011) Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 26:19-26
25. Burmester GR, Feist E, Sleeman MA, Wang B, White B, Magrini F (2011) Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-alpha, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study. Ann Rheum Dis 70:1542-1549
26. Joshi A, Bauer R, Kuebler P, White M, Leddy C, Compton P, Garovoy M, Kwon P, Walicke P, Dedrick R (2006) An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis. J Clin Pharmacol 46:10-20 (Pubitemid 43021710)
27. Rodionov N (2000) Graph digitizer version 1.9. http://download.cnet.com/ Graph-Digitizer/3000-2054-4-10073591.html. Accessed 14 July 2014
28. D'Argenio DZ, Schumitzky A (2009) ADAPT 5 user's guide: pharmacokinetic/pharmacodynamic system analysis Software. Biomedical Simulations Resource, Los Angeles
29. Deli MA (2009) Potential use of tight junction modulators to reversibly open membranous barriers and improve drug delivery. Biochim Biophys Acta Biomembr 1788:892-910
30. Beyer I, van Rensburg R, Strauss R, Li Z, Wang H, Persson J, Yumul R, Feng Q, Song H, Bartek J, Fender P, Lieber A (2011) Epithelial junction opener JO-1 improves monoclonal antibody therapy of cancer. Cancer Res 71:7080-7090
31. McNulty M, Singh RJ, Li X, Bergstralh EJ, Kumar R (2011) Determination of serum and plasma sclerostin concentrations by enzyme-linked immunoassays. J Clin Endocrinol Metab 96:E1159-E1162
32. Yan X, Mager DE, Krzyzanski W (2010) Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models. J Pharmacokinet Pharmacodyn 37:25-47
33. Wiig H, Kaysen GA, al-Bander HA, De Carlo M, Sibley L, Renkin EM (1994) Interstitial exclusion of IgG in rat tissues estimated by continuous infusion. Am J Physiol 266:H212-H219
34. Wiig H, Tenstad O (2001) Interstitial exclusion of positively and negatively charged IgG in rat skin and muscle. Am J Physiol Heart Circ Physiol 280:H1505-H1512
35. Wiig H, Swartz MA (2012) Interstitial fluid and lymph formation and transport: physiological regulation and roles in inflammation and cancer. Physiol Rev 92:1005-1060
36. Nakahara T, Norberg SM, Shalinsky DR, Hu-Lowe DD, McDonald DM (2006) Effect of inhibition of vascular endothelial growth factor signaling on distribution of extravasated antibodies in tumors. Cancer Res 66:1434-1445 (Pubitemid 43259924)
37. Thurber GM, Schmidt MM, Wittrup KD (2008) Factors determining antibody distribution in tumors. Trends Pharmacol Sci 29:57-61
38. Thurber GM, Schmidt MM, Wittrup KD (2008) Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv Drug Deliv Rev 60:1421-1434
39. Baker JH, Lindquist KE, Huxham LA, Kyle AH, Sy JT, Minchinton AI (2008) Direct visualization of heterogeneous extravascular distribution of trastuzumab in human epidermal growth factor receptor type 2 overexpressing xenografts. Clin Cancer Res 14:2171-2179 (Pubitemid 351551130)